| ²é¿´: 297 | »Ø¸´: 3 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
herinͳæ (СÓÐÃûÆø)
|
[½»Á÷]
¡¾ÆäËû¡¿ÇëÎʸ÷λ´óÏÀ3.2.R.1.P.2 Information on ComponentsÎÊÌâ
|
||
| ÇëÎʸ÷λ´óÏÀ3.2.R.1.P.2 Information on ComponentsÖÐÓ¦¸Ã°üº¬ÄÄЩÐÅÏ¢°¡£¿Ö»ÊÇÔÁÏÒ©ºÍ¸¨ÁϵÄÂð£¿Òª²»Òª»¹Ìṩ°ü²ÄµÄÐÅÏ¢ÁË£¬¼±ÅΰïÖú£¡ |
» ²ÂÄãϲ»¶
ҩѧ¿¼Ñе÷¼Á
ÒѾÓÐ0È˻ظ´
»ªÄÏÀí¹¤´óѧ-ҽѧԺ-ҩѧר˶ÉÙÁ¿µ÷¼ÁÃû¶î
ÒѾÓÐ28È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ149È˻ظ´
ÇóÖú¡¶ÉúÎïÀûÓöȺÍÉúÎïµÈЧÐÔÑо¿Ö¸µ¼ÔÔò¡·£¨ÊÔ ÐУ©£¬2002
ÒѾÓÐ0È˻ظ´
ÎÄÏ×ÇóÖú
ÒѾÓÐ0È˻ظ´
herin
ͳæ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 250.2
- Ìû×Ó: 191
- ÔÚÏß: 3.6Сʱ
- ³æºÅ: 699572
- ×¢²á: 2009-02-11
4Â¥2009-07-25 10:42:47
gene112
½ð³æ (ÎÄ̳¾«Ó¢)
- Ó¦Öú: 3 (Ó×¶ùÔ°)
- ¹ó±ö: 0.04
- ½ð±Ò: 1459.9
- É¢½ð: 3800
- ºì»¨: 23
- ɳ·¢: 12
- Ìû×Ó: 12577
- ÔÚÏß: 845Сʱ
- ³æºÅ: 751817
- ×¢²á: 2009-04-18
- ÐÔ±ð: GG
- רҵ: Éñ¾±äÐÔ¡¢ÔÙÉú¼°Ïà¹Ø¼²²¡

2Â¥2009-07-01 18:09:50
llb1978
½ð³æ (ÕýʽдÊÖ)
- Ó¦Öú: 2 (Ó×¶ùÔ°)
- ½ð±Ò: 1364.2
- ºì»¨: 2
- Ìû×Ó: 462
- ÔÚÏß: 24.7Сʱ
- ³æºÅ: 92998
- ×¢²á: 2005-09-12
- ÐÔ±ð: GG
- רҵ: Ò©Îïѧ
¡ï ¡ï ¡ï ¡ï ¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
xuxuan(½ð±Ò+4,VIP+0):¹ÄÀø²ÎÓ뻥Öú.лл 7-3 19:57
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
xuxuan(½ð±Ò+4,VIP+0):¹ÄÀø²ÎÓ뻥Öú.лл 7-3 19:57
|
http://www.fda.gov/downloads/Dru ... erics/ucm120980.pdf What should be included in 3.2.R.1.P.2, Information on Components? COA¡¯s for drug substance, excipients and packaging components used to produce the exhibit batch. |

3Â¥2009-07-03 17:33:47














»Ø¸´´ËÂ¥